神州細胞(688520.SH):控股子公司產品SCT650C獲得澳大利亞Ia期臨牀試驗倫理許可
格隆匯5月25日丨神州細胞(688520.SH)公佈,公司控股子公司神州細胞工程有限公司(簡稱“神州細胞工程”)收到澳大利亞人類臨牀研究倫理委員會(HREC)簽發的關於批准公司自主研發的重組抗IL-17單克隆抗體注射液(項目代號:SCT650C)開展Ia期臨牀試驗的臨牀試驗倫理許可,並將向澳大利亞藥品管理局(TGA)進行臨牀試驗備案。根據澳大利亞藥品註冊相關法律法規要求,臨牀試驗備案完成後,公司即可開展該產品Ia期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.